FULL TEXT LINKS



Review > J Control Release. 2021 Jan 10;329:758-761. doi: 10.1016/j.jconrel.2020.10.009. Epub 2020 Oct 7.

Ivermectin: an award-winning drug with expected antiviral activity against COVID-19

Fabio Rocha Formiga ¹, Roger Leblanc ², Juliana de Souza Rebouças ³, Leonardo Paiva Farias ⁴, Ronaldo Nascimento de Oliveira ⁵, Lindomar Pena ⁶

Affiliations

Affiliations

- Department of Immunology, Aggeu Magalhães Institute (IAM), Oswaldo Cruz Foundation (FIOCRUZ), 50670-420 Recife, PE, Brazil; Graduate Program in Applied Cellular and Molecular Biology, University of Pernambuco (UPE), 50100-130 Recife, PE, Brazil. Electronic address: fabio.formiga@fiocruz.br.
- 2 Department of Chemistry, University of Miami, 1301 Memorial Drive, Coral Gables, FL 33146, USA
- 3 Institute of Biological Sciences, University of Pernambuco (UPE), 50100-130 Recife, PE, Brazil.
- ⁴ Laboratory of Inflammation and Biomarkers, Gonçalo Moniz Institute (IGM), Oswaldo Cruz Foundation (FIOCRUZ), 40296-710 Salvador, BA, Brazil.
- 5 Bioactive Compounds Synthesis Laboratory, Department of Chemistry, Federal Rural University of Pernambuco (UFRPE), 52171-900 Recife, PE, Brazil.
- Department of Virology, Aggeu Magalhães Institute (IAM), Oswaldo Cruz Foundation (FIOCRUZ), 50670-420 Recife, PE, Brazil.

PMID: 33038449 PMCID: PMC7539925 DOI: 10.1016/j.jconrel.2020.10.009

Free PMC article

Abstract

Ivermectin is an FDA-approved broad-spectrum antiparasitic agent with demonstrated antiviral activity against a number of DNA and RNA viruses, including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Despite this promise, the antiviral activity of ivermectin has not been consistently proven in vivo. While ivermectin's activity against SARS-CoV-2 is currently under investigation in patients, insufficient emphasis has been placed on formulation challenges. Here, we discuss challenges surrounding the use of ivermectin in the context of coronavirus disease-19 (COVID-19) and how novel formulations employing micro- and nanotechnologies may address these concerns.

Copyright © 2020 Elsevier B.V. All rights reserved.

Figures

FOLLOW NCBI



Follow NLM


National Library of Medicine 8600 Rockville Pike Bethesda, MD 20894

Copyright FOIA Privacy

Help Accessibility Careers

NLM NIH HHS USA.gov

1 of 2 5/26/2021, 8:41 AM



Related information

MedGen

PubChem Compound (MeSH Keyword)

LinkOut - more resources

Full Text Sources

Elsevier Science Europe PubMed Central Ovid Technologies, Inc. PubMed Central

Medical

MedlinePlus Health Information

Miscellaneous

NCI CPTAC Assay Portal

2 of 2 5/26/2021, 8:41 AM